|
Index | - | P/E | 1.23 | EPS (ttm) | 0.45 | Insider Own | 33.90% | Shs Outstand | 6.22M | Perf Week | -13.47% |
Market Cap | 13.61M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | - | Perf Month | -48.24% |
Income | 2.90M | PEG | - | EPS next Q | - | Inst Own | 14.50% | Short Float | - | Perf Quarter | -60.44% |
Sales | - | P/S | - | EPS this Y | 978.50% | Inst Trans | - | Short Ratio | 0.77 | Perf Half Y | -63.45% |
Book/sh | 0.30 | P/B | 1.85 | EPS next Y | - | ROA | 22.50% | Target Price | - | Perf Year | -95.80% |
Cash/sh | 0.00 | P/C | - | EPS next 5Y | - | ROE | 107.10% | 52W Range | 0.57 - 17.12 | Perf YTD | -88.22% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -96.77% | Beta | -0.11 |
Dividend % | - | Quick Ratio | 0.70 | Sales past 5Y | - | Gross Margin | - | 52W Low | -3.32% | ATR | 0.10 |
Employees | - | Current Ratio | 0.70 | Sales Q/Q | -70.90% | Oper. Margin | - | RSI (14) | 27.92 | Volatility | 10.16% 10.20% |
Optionable | No | Debt/Eq | 0.26 | EPS Q/Q | -197.80% | Profit Margin | - | Rel Volume | 0.88 | Prev Close | 0.60 |
Shortable | Yes | LT Debt/Eq | 0.26 | Earnings | - | Payout | 0.00% | Avg Volume | 940.29K | Price | 0.55 |
Recom | - | SMA20 | -39.93% | SMA50 | -47.35% | SMA200 | -76.07% | Volume | 836,654 | Change | -7.08% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite